NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free CTNM Stock Alerts $15.50 +0.54 (+3.61%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$14.75▼$15.6650-Day Range N/A52-Week Range$13.27▼$16.09Volume63,002 shsAverage Volume54,430 shsMarket Capitalization$283.03 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsSocial Media Get Contineum Therapeutics alerts: Email Address Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Contineum TherapeuticsContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Read More CTNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTNM Stock News HeadlinesMay 16 at 4:05 PM | businesswire.comContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 11, 2024 | investing.comContineum Therapeutics Inc (CTNM)May 8, 2024 | americanbankingnews.comContineum Therapeutics, Inc.'s (NASDAQ:CTNM) Quiet Period Will Expire on May 15thMay 2, 2024 | finance.yahoo.comContineum Therapeutics Announces Pricing of Initial Public OfferingSee More Headlines Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/18/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTNM CUSIPN/A CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$30.00 Low Stock Price Target$25.00 Potential Upside/Downside+80.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,260,000Free FloatN/AMarket Cap$283.03 million OptionableN/A BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Carmine N. Stengone MBA (Age 48)MS, President, CEO, Secretary & Director Comp: $790.3kMr. Peter T. Slover CPA (Age 49)Chief Financial Officer Comp: $569.7kDr. Daniel S. Lorrain Ph.D. (Age 55)Chief Science Officer Comp: $565.02kDr. Stephen L. Huhn F.A.A.P (Age 63)F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development Mr. Austin Chen Ph.D.SVP & Head of ResearchMr. Michael MayberrySenior Director & Corporate ControllerMore ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSESSA PharmaNASDAQ:EPIXEnanta PharmaceuticalsNASDAQ:ENTARani TherapeuticsNASDAQ:RANI23andMeNASDAQ:MEView All Competitors CTNM Stock Analysis - Frequently Asked Questions Should I buy or sell Contineum Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Contineum Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CTNM shares. View CTNM analyst ratings or view top-rated stocks. What is Contineum Therapeutics' stock price target for 2024? 3 brokers have issued 1 year price targets for Contineum Therapeutics' stock. Their CTNM share price targets range from $25.00 to $30.00. On average, they expect the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 80.6% from the stock's current price. View analysts price targets for CTNM or view top-rated stocks among Wall Street analysts. How have CTNM shares performed in 2024? Contineum Therapeutics' stock was trading at $15.40 at the start of the year. Since then, CTNM shares have increased by 0.6% and is now trading at $15.50. View the best growth stocks for 2024 here. When is Contineum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024. View our CTNM earnings forecast. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $110 million in an initial public offering (IPO) on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00 per share. When did the company's quiet period expire? Contineum Therapeutics' quiet period expired on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its IPO on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTNM) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersNext President (Not Trump. Not Biden.)The Freeport SocietyA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.